Use of direct-Acting antiviral agents in hepatitis C virusinfected liver transplant candidates

Chiranjeevi Gadiparthi, George Cholankeril, Brandon J. Perumpail, Eric R. Yoo, Sanjaya Satapathy, Satheesh Nair, Aijaz Ahmed

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Since the advent of direct acting antiviral (DAA) agents, chronic hepatitis C virus (HCV) treatment has evolved at a rapid pace. In contrast to prior regimen involving ribavirin and pegylated interferon, these newer agents are highly effective, well-Tolerated, have shorter course of therapy and safer essentially in all HCV patients including those with advanced liver disease and following liver transplantation. Clinicians caring for HCV-infected patients on the liver transplant (LT) waitlist are often faced with a dilemma whether to treat HCV infection before or after liver transplantation. Sustained virological response (SVR) rates following HCV treatment may improve hepatic function sufficiently enough to negate the need for LT in certain patients. On the other hand, the decrease in MELD without improvement in quality of life in certain patients may lead to delay or dropout from potentially curative LT surgery list. In this context, our review focuses on the approach to and optimal timing of DAA-based treatment of HCV infection in LT candidates in the peri-Transplant period.

Original languageEnglish (US)
Pages (from-to)315-322
Number of pages8
JournalWorld Journal of Gastroenterology
Volume24
Issue number3
DOIs
StatePublished - Jan 21 2018

Fingerprint

Hepatitis C
Hepacivirus
Antiviral Agents
Transplants
Liver
Virus Diseases
Liver Transplantation
Ribavirin
Chronic Hepatitis C
Therapeutics
Interferons
Liver Diseases
Quality of Life

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Use of direct-Acting antiviral agents in hepatitis C virusinfected liver transplant candidates. / Gadiparthi, Chiranjeevi; Cholankeril, George; Perumpail, Brandon J.; Yoo, Eric R.; Satapathy, Sanjaya; Nair, Satheesh; Ahmed, Aijaz.

In: World Journal of Gastroenterology, Vol. 24, No. 3, 21.01.2018, p. 315-322.

Research output: Contribution to journalReview article

Gadiparthi, Chiranjeevi ; Cholankeril, George ; Perumpail, Brandon J. ; Yoo, Eric R. ; Satapathy, Sanjaya ; Nair, Satheesh ; Ahmed, Aijaz. / Use of direct-Acting antiviral agents in hepatitis C virusinfected liver transplant candidates. In: World Journal of Gastroenterology. 2018 ; Vol. 24, No. 3. pp. 315-322.
@article{9549a2d65bd444afb0660d88733d1556,
title = "Use of direct-Acting antiviral agents in hepatitis C virusinfected liver transplant candidates",
abstract = "Since the advent of direct acting antiviral (DAA) agents, chronic hepatitis C virus (HCV) treatment has evolved at a rapid pace. In contrast to prior regimen involving ribavirin and pegylated interferon, these newer agents are highly effective, well-Tolerated, have shorter course of therapy and safer essentially in all HCV patients including those with advanced liver disease and following liver transplantation. Clinicians caring for HCV-infected patients on the liver transplant (LT) waitlist are often faced with a dilemma whether to treat HCV infection before or after liver transplantation. Sustained virological response (SVR) rates following HCV treatment may improve hepatic function sufficiently enough to negate the need for LT in certain patients. On the other hand, the decrease in MELD without improvement in quality of life in certain patients may lead to delay or dropout from potentially curative LT surgery list. In this context, our review focuses on the approach to and optimal timing of DAA-based treatment of HCV infection in LT candidates in the peri-Transplant period.",
author = "Chiranjeevi Gadiparthi and George Cholankeril and Perumpail, {Brandon J.} and Yoo, {Eric R.} and Sanjaya Satapathy and Satheesh Nair and Aijaz Ahmed",
year = "2018",
month = "1",
day = "21",
doi = "10.3748/wjg.v24.i3.315",
language = "English (US)",
volume = "24",
pages = "315--322",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "3",

}

TY - JOUR

T1 - Use of direct-Acting antiviral agents in hepatitis C virusinfected liver transplant candidates

AU - Gadiparthi, Chiranjeevi

AU - Cholankeril, George

AU - Perumpail, Brandon J.

AU - Yoo, Eric R.

AU - Satapathy, Sanjaya

AU - Nair, Satheesh

AU - Ahmed, Aijaz

PY - 2018/1/21

Y1 - 2018/1/21

N2 - Since the advent of direct acting antiviral (DAA) agents, chronic hepatitis C virus (HCV) treatment has evolved at a rapid pace. In contrast to prior regimen involving ribavirin and pegylated interferon, these newer agents are highly effective, well-Tolerated, have shorter course of therapy and safer essentially in all HCV patients including those with advanced liver disease and following liver transplantation. Clinicians caring for HCV-infected patients on the liver transplant (LT) waitlist are often faced with a dilemma whether to treat HCV infection before or after liver transplantation. Sustained virological response (SVR) rates following HCV treatment may improve hepatic function sufficiently enough to negate the need for LT in certain patients. On the other hand, the decrease in MELD without improvement in quality of life in certain patients may lead to delay or dropout from potentially curative LT surgery list. In this context, our review focuses on the approach to and optimal timing of DAA-based treatment of HCV infection in LT candidates in the peri-Transplant period.

AB - Since the advent of direct acting antiviral (DAA) agents, chronic hepatitis C virus (HCV) treatment has evolved at a rapid pace. In contrast to prior regimen involving ribavirin and pegylated interferon, these newer agents are highly effective, well-Tolerated, have shorter course of therapy and safer essentially in all HCV patients including those with advanced liver disease and following liver transplantation. Clinicians caring for HCV-infected patients on the liver transplant (LT) waitlist are often faced with a dilemma whether to treat HCV infection before or after liver transplantation. Sustained virological response (SVR) rates following HCV treatment may improve hepatic function sufficiently enough to negate the need for LT in certain patients. On the other hand, the decrease in MELD without improvement in quality of life in certain patients may lead to delay or dropout from potentially curative LT surgery list. In this context, our review focuses on the approach to and optimal timing of DAA-based treatment of HCV infection in LT candidates in the peri-Transplant period.

UR - http://www.scopus.com/inward/record.url?scp=85040729402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040729402&partnerID=8YFLogxK

U2 - 10.3748/wjg.v24.i3.315

DO - 10.3748/wjg.v24.i3.315

M3 - Review article

VL - 24

SP - 315

EP - 322

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 3

ER -